Business
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics
About this update from Quantum Cyber N.v.
[{"type":"text","content":"BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May: Commencement of Voluntary Quarterly Reporting:Under the disclosure requirements of the U.S. NASDAQ listing, foreign issuers are required to disclose full year financial results (20-F). In addition, Mainz Biomed will commence voluntary quarterly reporting with the release of its Q1 2023 financial results. The Q1 results will be announced on May 16, 2023. Presentation at Equity Forum Spring Conference 2023:CEO Guido Baechler will present at the Equity Forum Spring Conference 2023 in Frankfurt, Germany, on Wednesday, May 17, 2023, and will be available for meetings with investors at the Forum on Tuesday and Wednesday, May 16 & 17: Equity Forum Spring Conference 2023May 15-17, 2023Frankfurt am Main, Germany, Le MeridienCompany presentation: May 17, Session I, 7:45 a.m. EThttps://equityforum.de/events/fr-hjahrskonferenz-2023 \"After a successful start to the year with the expansion of sales activities in Germany, the commencement of new laboratory partnerships and the development of further European markets, we are focused on implementing our strategy to expand our commercial business in Europe and to advance the approval process in the US, as announced. The Board and Management are committed to continue to execute the business plan to grow shareholder value. I look forward to the upcoming results of our eAArly Detect study to demonstrate the potential of our new biomarkers and also to face-to-face interactions with existing and potential new investors,\" said Guido Baechler, Chief Executive Officer of Mainz Biomed. Mainz Biomed is currently commercializing its flagship product ColoAlert®, a highly efficacious and easy-to-use detection test for colorectal cancer (CRC) in select international territories and in December of 2022, initiated a U.S. Pivotal Clinical Study (ReconAAsense) for a CRC screening test that may integrate the Company’s portfolio of novel gene expression (mRNA) biomarkers. These biomarkers have demonstrated potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC that are being evaluated in European and U.S. studies...